Management of adult acute lymphoblastic leukemia: Moving toward a risk-adapted approach

Amit Verma, Wendy Stock

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

The vast majority of adults with acute lymphoblastic leukemia (ALL) now achieve remission with current intensive chemotherapy regimens. Nevertheless, most adults with ALL will eventually relapse and die of their disease. Specific clinical and molecular-cytogenetic prognostic factors have been identified that are beginning to provide insights for the development of risk-adapted management strategies that appear to improve survival for several high-risk patient groups, including those with mature B-cell ALL and B-lineage ALL patients with a Philadelphia chromosome. We review standard and some recently described prognostic factors in adult ALL, describe current therapy based on a risk-adapted approach, and look toward the future with a brief discussion of novel, targeted treatments that could be incorporated into postremission strategies to improve survival for adults with ALL.

Original languageEnglish (US)
Pages (from-to)14-20
Number of pages7
JournalCurrent Opinion in Oncology
Volume13
Issue number1
DOIs
StatePublished - Jan 30 2001
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Management of adult acute lymphoblastic leukemia: Moving toward a risk-adapted approach'. Together they form a unique fingerprint.

Cite this